|Articles|December 16, 2013
- BioPharm International-12-16-2013
- Volume 2013 eBook
- Issue 1
Creating Better Medicines through Better Conjugation
Author(s)Cynthia A. Challener
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.
Advertisement
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.
from BioPharm International’s 2013 Innovation Updates and Strategies eBook.
Articles in this issue
almost 12 years ago
Recovering Patent Life with Patent Term Extensionalmost 12 years ago
Strategic Outsourcing in Clinical Developmentalmost 12 years ago
Leveraging Development Strengths Drives Therapies to Marketalmost 12 years ago
Driving Innovation in Biopharmaceuticalsalmost 12 years ago
Crowdfunding Biopharmaceutical Innovationalmost 12 years ago
Restructuring for Biopharmaceutical SuccessNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Big Biopharma Investment in CGTs Will Redefine the Industry Pipeline
2
Report - Digital Transformation in Biopharma: The Gap Between Hype and Implementation
3
AstraZeneca Next to Agree to MFN Deal: Report
4
BioPharm Weekly News Roundup—Week of Oct. 6, 2025
5
